Fig. 6

Variations of human immune cell distribution in the spleen and BM of treated and untreated HTM. Immune cell subsets in the spleen (a) and BM (b) of differently treated HTM are imaged. Data are shown as mean ± SEM and significances were analyzed using Tukey‘s multiple comparison test (*p < 0.05; **p < 0.01). c CD4/CD8 ratio of CD3⁺ t cells isolated from the spleen of untreated and B100 treated HTM were compared and significance is indicated (Student’s T-test; p = 0.0148). Percentage of human hematopoietic cells (CD45⁺; d), immune cell subsets (e) and CD4/CD8 ratio (f) of HTM in the spleen of responder (no tumor) and non-responder (tumor) of all mAb treated mice. Significant difference was calculated by Student’s T-test (p = 0.0197). Trast, trastuzumab; Pert, pertuzumab